Responder Analysis of the Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

BACKGROUND: Men with prostate cancer are at risk of experiencing accelerated bone loss and fractures as a result of androgen deprivation therapy (ADT). OBJECTIVE: We evaluated the effects of denosumab, a fully human monoclonal antibody against RANKL, on preservation of BMD at 3 key skeletal sites (l...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Egerdie, Blair, Saad, Fred, Smith, Matthew R, Tammela, Teuvo LJ, Heracek, Jiri, Sieber, Paul, Ke, Chunlei, Leder, Benjamin, Dansey, Roger, Goessl, Carsten
Format: Artigo
Jezik:Inglês
Izdano: 2012
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3671885/
https://ncbi.nlm.nih.gov/pubmed/22641239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/pcan.2012.18
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items